Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOTRIMIN vs LOTRIMIN AF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Clotrimazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Topical treatment of tinea pedis, tinea cruris, tinea corporis, tinea versicolor, and cutaneous candidiasis,Vaginal treatment of vulvovaginal candidiasis
Tinea pedis,Tinea cruris,Tinea corporis,Pityriasis versicolor,Cutaneous candidiasis
Clotrimazole 1% cream or solution applied topically to affected area twice daily for 2-4 weeks. For vaginal tablets: 100 mg intravaginally once daily for 7 days or 500 mg single dose. For troches: 10 mg troche dissolved slowly in mouth five times daily for 14 days.
Topical: Apply twice daily (morning and evening) to affected area for 2-4 weeks. Intravaginal: One 200 mg suppository vaginally at bedtime for 3 days, or one 500 mg vaginal tablet as a single dose.
Terminal elimination half-life is approximately 20-50 hours. Dose adjustments not required in renal impairment, but caution in hepatic impairment.
Terminal elimination half-life of absorbed clotrimazole is approximately 3.5–4 hours, but this is clinically irrelevant due to negligible systemic absorption after topical application.
Hepatic metabolism via CYP3A4 and CYP2C9; excreted in feces and urine as metabolites.
Minimal systemic absorption; primarily local metabolism.
Approximately 70% of absorbed dose is excreted in feces as unchanged drug and metabolites; about 20% is excreted renally as metabolites with less than 1% unchanged. Biliary excretion is a minor route.
Less than 1% of topical clotrimazole is absorbed; absorbed drug is metabolized in the liver to inactive metabolites and excreted primarily in feces (approximately 69%) and urine (approximately 21%) via biliary and renal routes.
Approximately 98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 90–95% bound to plasma proteins, primarily albumin.
Volume of distribution is approximately 2.5-4.0 L/kg, indicating extensive tissue distribution.
Vd is approximately 2.5 L/kg after intravenous administration (data for systemic formulation); after topical application, systemic absorption is negligible (<1%), so Vd is not clinically meaningful.
Topical: minimal systemic absorption (<0.5%). Oral: not available; vaginal: approximately 3-10% systemic absorption.
Topical: Systemic bioavailability is <1% after application to intact skin; vaginal tablet: approximately 3–10% absorbed systemically.
No dose adjustment required for topical or vaginal use. For troches, no data available; however, systemic absorption is minimal.
No dosage adjustment required for renal impairment.
No dose adjustment required for topical or vaginal use. For troches, use with caution in severe hepatic impairment due to limited data.
No dosage adjustment required for hepatic impairment.
Topical: Apply to affected area twice daily for 2-4 weeks (safe for all ages). Vaginal: Not recommended in prepubertal children. Troches: Not recommended for children under 5 years due to risk of choking; for children ≥5 years, same dose as adults (10 mg troche five times daily).
Children ≥2 years: Same as adult dosing for topical application. Children <2 years: Not recommended without physician consultation.
No specific dose adjustment required. Use same dosing as adults. Consider skin fragility with topical application.
No specific dose adjustment; use same adult dosing with consideration of renal/hepatic function and potential drug interactions.
None
None
For external use only; avoid contact with eyes; discontinue if hypersensitivity occurs; not for ophthalmic or oral use; use in pregnancy only if clearly needed (Category B).
For external use only,Avoid contact with eyes,Discontinue if irritation occurs,Not for vaginal or oral use
Hypersensitivity to clotrimazole or any component of the formulation
Hypersensitivity to clotrimazole or any component
No known significant food interactions.
No clinically significant food interactions for topical clotrimazole.
Clotrimazole (LOTRIMIN) topical use is not associated with increased risk of major congenital malformations. Systemic absorption is minimal (<0.5% after vaginal or topical application). First trimester vaginal use has insufficient data, but no clear teratogenic signal. Second and third trimester vaginal use is considered safe. Overall, risk is low due to negligible systemic exposure.
Clotrimazole (Lotrimin AF) is category B. No evidence of teratogenicity in animal studies. Limited human data from topical use in first trimester show no increased risk of major malformations. Systemic absorption from topical application is minimal (<0.5%), making fetal exposure negligible. No known fetal risks from topical use in any trimester.
Minimal systemic absorption after topical or vaginal use leads to negligible excretion into breast milk. M/P ratio is not applicable due to undetectable levels. Suitable for use during breastfeeding. No adverse effects reported in nursing infants.
Topical clotrimazole is considered compatible with breastfeeding. Systemic absorption is minimal, and any excreted amounts in breast milk are negligible. M/P ratio is not available due to minimal absorption. Avoid application to breast area to prevent infant oral contact.
No dose adjustment required during pregnancy. Pharmacokinetics of topical/vaginal clotrimazole are unchanged due to minimal systemic absorption. Standard dosing (e.g., 100 mg vaginal tablet for 7 days or 500 mg single dose) is appropriate.
No dose adjustment required for topical clotrimazole during pregnancy. Pharmacokinetics are not significantly altered as systemic absorption is minimal. Use standard dosing for indication (e.g., 1% cream twice daily for 2-4 weeks for dermatophytosis).
Clotrimazole is a broad-spectrum antifungal agent; Topical formulations (cream, solution, lotion) are preferred for dermatophytosis; Vaginal tablets must be inserted high into the vagina; Avoid use on broken or inflamed skin; Monitor for local irritation.
Lotrimin AF (clotrimazole) is a topical antifungal used for dermatophyte and yeast infections. For tinea pedis, apply twice daily for 4 weeks; shorter courses may lead to recurrence. Do not use in or near eyes. Avoid occlusive dressings unless directed.
Apply the medication to the affected area as directed, usually twice daily.,Wash hands before and after application unless treating hands.,For vaginal tablets, insert one tablet deep into the vagina at bedtime for 3 or 7 days.,Complete the full course even if symptoms improve.,Avoid tight-fitting clothing and synthetic fabrics; keep area clean and dry.
Apply a thin layer to affected skin twice daily, morning and evening.,Wash hands before and after application unless treating hands.,Continue use for the full prescribed duration even if symptoms improve.,Avoid contact with eyes, mouth, or open wounds.,Do not cover treated area with bandages or plastic unless instructed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOTRIMIN vs LOTRIMIN AF, answered by our medical review team.
LOTRIMIN is a Topical Antifungal that works by Clotrimazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.. LOTRIMIN AF is a Topical Antifungal that works by Inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOTRIMIN and LOTRIMIN AF depend on the specific clinical indication. These are both Topical Antifungal agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOTRIMIN is: Clotrimazole 1% cream or solution applied topically to affected area twice daily for 2-4 weeks. For vaginal tablets: 100 mg intravaginally once daily for 7 days or 500 mg single dose. For troches: 10 mg troche dissolved slowly in mouth five times daily for 14 days.. The standard adult dose of LOTRIMIN AF is: Topical: Apply twice daily (morning and evening) to affected area for 2-4 weeks. Intravaginal: One 200 mg suppository vaginally at bedtime for 3 days, or one 500 mg vaginal tablet as a single dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOTRIMIN and LOTRIMIN AF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOTRIMIN is classified as Category C. Clotrimazole (LOTRIMIN) topical use is not associated with increased risk of major congenital malformations. Systemic absorption is minimal (<0.5% after vaginal or topical applicat. LOTRIMIN AF is classified as Category C. Clotrimazole (Lotrimin AF) is category B. No evidence of teratogenicity in animal studies. Limited human data from topical use in first trimester show no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.